Results 71 to 80 of about 10,859 (138)

Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement

Haematologica, 2000
BACKGROUND AND OBJECTIVES: The detection of CBFbeta/MYH11 transcripts by RT-PCR has became a valuable and widely used technique in the accurate cytogenetic and molecular classification of acute myeloid leukemia (AML), but the clinical value of RT-PCR for
G Martin, E Barragan, P Bolufer, C Chillon, R Garcia-Sanz, T Gomez, S Brunet, M Gonzalez, MA Sanz   +8 more
doaj  

Stable thyroid cancer in a patient with thoracic aortic aneurysm and MYH11 variation

Endocrinology, Diabetes & Metabolism Case Reports
We report the case of a male patient with papillary thyroid cancer, familial thoracic aortic aneurysm and dissection, and a variation in the MYH11 gene. Because of considerable tumor bulk in the neck that was not resectable, the patient underwent partial
Vahab Fatourechi, Amy A Swanson, Robert A Lee   +2 more
doaj   +1 more source

Deciphering the tumor immune microenvironment: single-cell and spatial transcriptomic insights into cervical cancer fibroblasts

Journal of Experimental & Clinical Cancer Research
Background Cervical cancer (CC) remains a significant global health challenge despite advancements in screening, HPV vaccination, and therapeutic strategies. Tumor heterogeneity, driven by epigenetic modifications, affects immune evasion, metastasis, and
Zhiheng Lin, Youwei Zhou, Zhenran Liu, Wenyang Nie, Hengjie Cao, Shengnan Li, Xuanling Li, Lijun Zhu, Guangyao Lin, Yanyu Ding, Yi Jiang, Zuxi Gu, Lianwei Xu, Zhijie Zhao, Huabao Cai   +14 more
doaj   +1 more source

Fusion-specific co-mutational architecture and treatment-response associations in pediatric core-binding factor acute myeloid leukemia: a multicenter exome-profiled cohort

Frontiers in Oncology
IntroductionCore-binding factor acute myeloid leukemia (CBF-AML) is defined by one of two founding fusions, but cooperating lesions may differ between fusion subtypes.
Mei Li, Chunxia Cai, Chunping Wu, Xiaoqin Feng, Mincui Zheng, Huirong Mai, Lihua Yang, Xiangling He, Hong Wen, Shaohua Le, Nainong Li, Yongzhi Zheng   +11 more
doaj   +1 more source

Marked Bone Marrow Eosinophilia Post‐Azacitidine + Ivosidenib Treatment for Acute Myeloid Leukemia

International Journal of Laboratory Hematology, Volume 48, Issue 5, Page 921-923, October 2026.
Christopher Liwski, Curtis Marcoux, David M. Conrad   +2 more
wiley   +1 more source

Molecular monitoring to identify a threshold of CBFbeta/MYH11 transcript below which continuous complete remission of acute myeloid leukemia inv16 is likely

Haematologica, 2004
Many patients with the inv(16) positive acute myeloid leukemia (AML) achieve complete remission (CR). Using real-time reverse transcriptase polymerase chain reaction (RT-PCR), we previously proposed critical CBFbeta-MYH11 transcript copy number ...
G Martinelli, M Rondoni, S Buonamici, E Ottaviani, PP Piccaluga, M Malagola, M Baccarani   +6 more
doaj  

Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine. [PDF]

Blood Cancer J
Shi T, Xue R, Jia J, Liu M, Zhou Y, Geng C, Jian Y, Tian Y, Zhang Y, Li W, Huang L, Zhou H, Liu A, Gao W, Chen W, Leng Y, Wu Y, Zhu HH.   +17 more
europepmc   +1 more source

CBFβ-SMMHC–driven leukemogenesis requires enhanced RUNX1-DNA binding affinity in mice

The Journal of Clinical Investigation
The leukemia fusion gene CBFB-MYH11 requires RUNX1 for leukemogenesis, but the underlying mechanism is unclear. By in vitro studies, we found that CBFβ-SMMHC, the chimeric protein encoded by CBFB-MYH11, could enhance the binding affinity between RUNX1 ...
Tao Zhen, Yaqiang Cao, Tongyi Dou, Yun Chen, Guadalupe Lopez, Ana Catarina Menezes, Xufeng Wu, John A. Hammer, Jun Cheng, Lisa Garrett, Stacie Anderson, Martha Kirby, Stephen Wincovitch, Bayu Sisay, Abdel G. Elkahloun, Di Wu, Lucio H. Castilla, Wei Yang, Jiansen Jiang, Keji Zhao, P. Paul Liu   +20 more
doaj   +1 more source

FHL3 Regulates Vascular Smooth Muscle Cell Phenotypic Switching Through the MRTFB-SRF Signaling Axis. [PDF]

Cells
Huang X, Zhang H, Zhang Y, Solomon CU, McVey DG, Ye S.   +5 more
europepmc   +1 more source

The Inv(16) Oncogene CBFB::MYH11 is Required for the Survival of Leukemia Cells in the Blood and Spleen, but not the Bone Marrow. [PDF]

Oncogene
Panda S, Wang Y, Dogiparthi VR, Becker M, Dhir A, Lam C, Rivas C, Alemu L, Garrett L, Xiao P, Swenson SA, Hewitt KJ, Hyde RK.   +12 more
europepmc   +1 more source